SECsense Logo

AstraZeneca PLC Shareholding Update: Pascal Soriot's Vested Shares Report (May 2025)

$AZN
Form 6-K
Filed on: 2025-05-23
Source
AstraZeneca PLC Shareholding Update: Pascal Soriot's Vested Shares Report (May 2025)

Here are the key insights extracted from the provided financial report section regarding AstraZeneca PLC:

  1. Report Type and Date: This is a Form 6-K filed on May 23, 2025, which pertains to the month of May 2025.
  2. Company Information:
  • Name: AstraZeneca PLC
  • Location: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
  • Commission File Number: 001-11960.
  1. Director/PDMR Shareholding Notification:
  • Individual: Pascal Soriot, Executive Director and Chief Executive Officer.
  • Event Date: On May 21, 2025, an award of AstraZeneca's ordinary shares vested to Pascal Soriot under the AstraZeneca Performance Share Plan (AZPSP).
  1. Details of the Award:
  • The award was granted on May 21, 2020, with a three-year performance period followed by a two-year holding period.
  • 97% of the AZPSP award vested, with the remaining unvested portion lapsing.
  1. Shares Acquired:
  • Pascal Soriot acquired 8,970 ordinary shares through the AZPSP.
  • The fair market value of an ordinary share at the time of vesting was 10,418 pence.
  1. Tax Obligations: Shares were withheld to satisfy tax obligations that arose upon vesting.
  2. Transaction Details:
  • Nature of the Transaction: Acquisition of ordinary shares pursuant to the vesting under AZPSP, for nil consideration.
  • Place of Transaction: Outside a trading venue.
  1. Compliance and Regulation: The notification is compliant with EU Market Abuse Regulation requirements.
  2. Company Overview: AstraZeneca is a global biopharmaceutical company focusing on the discovery, development, and commercialization of prescription medicines primarily in oncology, rare diseases, and various therapeutic areas.

This summary captures the essential elements of the report concerning shareholding changes for a key executive at AstraZeneca and provides context about the company's operational focus and regulatory compliance.